GeneDx Holdings Corp
WGSWW0.042USD
-0.005-11.39%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of GeneDx Holdings Corp Company
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.
GeneDx Holdings Corp Info
Ticker SymbolWGSWW
Company nameGeneDx Holdings Corp
IPO dateSep 04, 2020
CEOMs. Katherine A. Stueland
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address333 Ludlow Street
CitySTAMFORD
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code06902
Phone18887291206
Websitehttps://sema4.com/
Ticker SymbolWGSWW
IPO dateSep 04, 2020
CEOMs. Katherine A. Stueland
Company Executives of GeneDx Holdings Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Thomas Fuchs
Dr. Thomas Fuchs
Director
Director
--
--
Mr. Jason Michael Ryan, CPA
Mr. Jason Michael Ryan, CPA
Chairman of the Board
Chairman of the Board
--
--
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
--
--
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
--
--
Ms. Katherine A. Stueland
Ms. Katherine A. Stueland
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bryan Dechairo
Dr. Bryan Dechairo
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Thomas Fuchs
Dr. Thomas Fuchs
Director
Director
--
--
Mr. Jason Michael Ryan, CPA
Mr. Jason Michael Ryan, CPA
Chairman of the Board
Chairman of the Board
--
--
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
--
--
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
--
--
Ms. Katherine A. Stueland
Ms. Katherine A. Stueland
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Jan 2
Updated: Fri, Jan 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
28
3.26M
0.00%
-1.58M
2025Q3
28
3.12M
0.00%
-1.44M
2025Q2
28
2.84M
0.00%
-1.51M
2025Q1
30
2.83M
0.00%
-2.32M
2024Q4
34
2.66M
0.00%
-2.17M
2024Q3
37
2.02M
0.00%
-4.83M
2024Q2
38
3.62M
0.00%
-3.20M
2024Q1
37
3.62M
0.00%
-3.40M
2023Q4
37
4.48M
0.00%
-3.37M
2023Q3
36
5.16M
0.00%
-2.70M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
LMR Partners LLP
2.14M
0%
+100.00K
+4.91%
Sep 30, 2025
D. E. Shaw & Co., L.P.
467.20K
0%
--
--
Sep 30, 2025
T. Rowe Price Associates, Inc.
243.78K
0%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
377.00
0%
-49.21K
-99.24%
Sep 30, 2025
Q Global Advisors, LLC
111.70K
0%
--
--
Sep 30, 2025
Wolverine Asset Management, LLC
35.37K
0%
+604.00
+1.74%
Sep 30, 2025
TD Asset Management Inc.
34.88K
0%
--
--
Sep 30, 2025
Alpine Global Management, LLC
20.00K
0%
--
--
Sep 30, 2025
Brown Advisory
10.83K
0%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of GeneDx Holdings Corp?
The top five shareholders of GeneDx Holdings Corp are:
LMR Partners LLP holds 2.14M shares, accounting for 0.00% of the total shares.
D. E. Shaw & Co., L.P. holds 467.20K shares, accounting for 0.00% of the total shares.
T. Rowe Price Associates, Inc. holds 243.78K shares, accounting for 0.00% of the total shares.
UBS Financial Services, Inc. holds 377.00 shares, accounting for 0.00% of the total shares.
Q Global Advisors, LLC holds 111.70K shares, accounting for 0.00% of the total shares.
LMR Partners LLP holds 2.14M shares, accounting for 0.00% of the total shares.
D. E. Shaw & Co., L.P. holds 467.20K shares, accounting for 0.00% of the total shares.
T. Rowe Price Associates, Inc. holds 243.78K shares, accounting for 0.00% of the total shares.
UBS Financial Services, Inc. holds 377.00 shares, accounting for 0.00% of the total shares.
Q Global Advisors, LLC holds 111.70K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of GeneDx Holdings Corp?
The top three shareholder types of GeneDx Holdings Corp are:
Other
Other
How many institutions hold shares of GeneDx Holdings Corp (WGSWW)?
As of 2025Q4, 28 institutions hold shares of GeneDx Holdings Corp, with a combined market value of approximately 3.26M, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for GeneDx Holdings Corp?
In --, the -- business generated the highest revenue for GeneDx Holdings Corp, amounting to -- and accounting for --% of total revenue.
